ArticleAnnals of medicine2025

Comparison of first-generation EGFR-TKIs combined with low-dose bevacizumab versus osimertinib in untreated advanced EGFR-mutated NSCLC.

Yingqi Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.